Daniel Vasella
Daniel Vasella
Daniel Lucius Vasella, M.D.is a medical doctor, author, and executive who served as CEO and chairman of the Swiss pharmaceutical company Novartis AG, the world's fifth largest drug company. During his tenure the Novartis shares declined 10%, below the industry...
fix problems quality quantity
We first want to fix the quality and quantity problems which are at hand.
address customer demand health increase meet plan public quality require research turn vaccines
Our plan is to turn around the Chiron vaccines business, which will require investments in research and development, and manufacturing, to increase quality and capacity, so that we can better meet customer demand and address public health needs,
although areas discussed explore hope time
At present, no collaboration has been discussed with Roche management, although we hope that over time we will be able to explore areas of collaboration.
healthy larger litigation
Litigation is potentially much larger when you vaccinate healthy people.
achieving based confident objectives record robust sales
Based on the robust results, we are are confident of achieving our full-year objectives for new record sales and earnings.
believe challenges entering exciting fair field help share solving
We are entering an exciting field with vaccines. Chiron has a fair share of challenges but I believe we can help them in solving those.
answer
It is a hypothetical question. I don't answer hypothetical questions.
confident delivering dynamic growth record sales year
We are confident of delivering in 2006 another year of dynamic growth with record sales and earnings.
plan turn vaccines
Our plan is to turn around the Chiron vaccines business,
growth increased investment key level marketing percent priority resulted sales
Our increased level of investment in marketing and sales, with the priority on key growth drivers, resulted in a sales growth of 21 percent in Pharmaceuticals in the U.S.,
anticipate dynamic fourth full growth looking operating quarter resulting sales softer solid somewhat third
Looking ahead, we anticipate a somewhat softer third quarter and, again, a more dynamic fourth quarter resulting in mid-single-digit sales growth... and solid operating growth for the full year,
continue expect gain growth market slow
Market growth in 2006 will slow down somewhat. I expect that we will be able to continue to gain market share.
concerned europe human resources
If you can't find the human resources in Europe you go elsewhere. As a European, I'm concerned for Europe.
business dynamic growth overall performance pleased strong third
I am pleased with the overall strong performance of our business in the third quarter, particularly the dynamic growth of Pharmaceuticals.